{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T03:34:06Z","timestamp":1780112046724,"version":"3.54.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T00:00:00Z","timestamp":1578441600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T00:00:00Z","timestamp":1578441600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s12094-019-02275-9","type":"journal-article","created":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T07:02:51Z","timestamp":1578466971000},"page":"1390-1398","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Analysis of mismatch repair (MMR) proteins expression in a series of malignant pleural mesothelioma (MPM) patients"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5068-3124","authenticated-orcid":false,"given":"S.","family":"Cedr\u00e9s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ponce-Aix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Iranzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Callejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Pardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Martinez-Marti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"G\u00f3mez-Abecia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. C.","family":"Zucchiatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Sansano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. B.","family":"Enguita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M.","family":"Miquel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Viaplana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Dienstmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Paz-Ares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Felip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,8]]},"reference":[{"key":"2275_CR1","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.jtho.2018.08.2036","volume":"11","author":"A Tsao","year":"2018","unstructured":"Tsao A, Lindwasser O, Adjei A, Adusimilli P, Beyers M, Blumenthal G, et al. Current and future management of malignant mesothelioma: a consensus report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and mesothelioma applied research foundation. J Thorac Oncol. 2018;11:1655\u201367.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"2275_CR2","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jtho.2015.11.005","volume":"11","author":"F Galateau-Salle","year":"2015","unstructured":"Galateau-Salle F, Churg A, Roggli V, Travis W, On behalf of the World Health Organization Committee for tumors of pleura. The 2015 Worl Health Organization classification of tumors of the pleural: advances since the 2004 classification. J Thorac Oncol. 2015;11(2):142\u201354.","journal-title":"J Thorac Oncol"},{"key":"2275_CR3","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","volume":"48","author":"R Bueno","year":"2016","unstructured":"Bueno R, Stawiski EW, Goldstein LD, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet. 2016;48:407\u201316.","journal-title":"Nat Genet"},{"issue":"12","key":"2275_CR4","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","volume":"8","author":"J Hmeljak","year":"2018","unstructured":"Hmeljak J, Sanchez-Vega F, Hoadley K, Shih J, Stewart C, et al. Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov. 2018;8(12):1548\u201365.","journal-title":"Cancer Discov"},{"key":"2275_CR5","doi-asserted-by":"crossref","unstructured":"Maio M, Scherpereel A, Calabro L, Aerts J, Cedres S, et al. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international. Randomized, double-blind, placebo-controlled phase 2b trial. Lancet Oncol. 2017:18(9):1261\u20131273","DOI":"10.1016\/S1470-2045(17)30446-1"},{"issue":"5","key":"2275_CR6","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","volume":"18","author":"E Alley","year":"2017","unstructured":"Alley E, Lopez J, Santoro A, Morosky A, Saraf S, et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised open-label, phase 1b trial. Lancet Oncol. 2017;18(5):623\u201330.","journal-title":"Lancet Oncol"},{"key":"2275_CR7","doi-asserted-by":"crossref","first-page":"8565","DOI":"10.1200\/JCO.2018.36.15_suppl.8565","volume":"36","author":"A Desai","year":"2018","unstructured":"Desai A, Karrison T, Rose B, Pemberton E, Hill B, et al. A phase II trial of pembrolizumab in patients with previously-treated mesothelioma (MM). J Clin Oncol. 2018;36:8565\u2013856.","journal-title":"J Clin Oncol"},{"key":"2275_CR8","first-page":"5","volume":"30","author":"S Popat","year":"2019","unstructured":"Popat S, Curioni-Fontecedro A, Polydoropoulou V, Shah R, O\u00b4Brien M, et al. A multicentre randomized pase III trial comparing pembrolizumab vs single agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: results from the European Thoracic Oncology Platform (ETOP9-15) PROMISE-meso trial. Ann Oncol. 2019;30:5.","journal-title":"Ann Oncol"},{"issue":"239","key":"2275_CR9","first-page":"253","volume":"20","author":"A Scherpereel","year":"2019","unstructured":"Scherpereel A, Greiller L, Lantuejoul S, et al. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501MAPS2): a multicenter, open-label, randomized, non-comparative, phase 2 trial. Lancet Oncol. 2019;20(239):253.","journal-title":"Lancet Oncol"},{"key":"2275_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(18)30420-X","author":"M Disselhorst","year":"2019","unstructured":"Disselhorst M, Quispel-Janssen J, Lalezani F, et al. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single arm, phase 2 trial. Lancet Resp Med. 2019. https:\/\/doi.org\/10.1016\/S2213-2600(18)30420-X.","journal-title":"Lancet Resp Med"},{"key":"2275_CR11","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1158\/1078-0432.CCR-19-0103","volume":"25","author":"M Okada","year":"2019","unstructured":"Okada M, Tm K, Aoe K, Kato T, Fujimoto N, et al. Clinical efficacy and safety of nivolumab: results of a multicenter, open label, single arm, Japanese phase II study in malignant pleural mesothelioma (MERIT). Clin Cancer Res. 2019;25:5485\u201392.","journal-title":"Clin Cancer Res"},{"key":"2275_CR12","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.canlet.2017.11.014","volume":"414","author":"F Teng","year":"2018","unstructured":"Teng F, Meng X, Kong L, Yu J. Progress and challenges of predictive biomarkers of antiPD-1\/PD-L1 immunotherapy: a systematic review. Cancer Lett. 2018;414:166\u201373.","journal-title":"Cancer Lett"},{"key":"2275_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0173-9","author":"D Camidge","year":"2019","unstructured":"Camidge D, Doebele R, Kerr K. Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC. Nat Rev Clin Oncol. 2019. https:\/\/doi.org\/10.1038\/s41571-019-0173-9.","journal-title":"Nat Rev Clin Oncol"},{"key":"2275_CR14","doi-asserted-by":"crossref","first-page":"e0121071","DOI":"10.1371\/journal.pone.0121071","volume":"16","author":"S Cedres","year":"2015","unstructured":"Cedres S, Ponce-Aix S, Zugazagoitia J, et al. Analysis of expression of programmed cell death ligand (PD-L1) in malignant pleural mesothelioma (MPM). PLoS ONE. 2015;16:e0121071.","journal-title":"PLoS ONE"},{"key":"2275_CR15","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/JTO.0000000000000177","volume":"9","author":"A Mansfield","year":"2014","unstructured":"Mansfield A, Roden A, Peikert T, Sheinin YM, Harrington SM, Krco CJ, et al. B7\u2013H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. J Thorac Oncol. 2014;9:1036\u201340.","journal-title":"J Thorac Oncol"},{"key":"2275_CR16","doi-asserted-by":"crossref","first-page":"8514","DOI":"10.1200\/JCO.2017.35.15_suppl.8514","volume":"35","author":"G Rivalland","year":"2017","unstructured":"Rivalland G, Chuan-Hao Kao S, Pavlakis N, et al. Outcomes ofanti-PD-1 therapy in mesothelioma and correlation with PD-L1 expression. Proc Am Soc Clin Oncol. 2017;35:8514.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2275_CR17","doi-asserted-by":"crossref","first-page":"S292","DOI":"10.1016\/j.jtho.2016.11.300","volume":"12","author":"J Quispel-Janssen","year":"2017","unstructured":"Quispel-Janssen J, Zago G, Schouten R, Buikhuisen W, et al. A phase II study of nivolumab in malignant pleural mesothelioma (NivoMes): with translational research (TR) biopsies. J Thorac Oncol. 2017;12:S292\u2013S293293.","journal-title":"J Thorac Oncol"},{"key":"2275_CR18","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1158\/1538-7445.AM2015-364","volume":"75","author":"G Guo","year":"2015","unstructured":"Guo G, Chmielecki J, Goparaju C, et al. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer Res. 2015;75:264\u2013269.","journal-title":"Cancer Res"},{"key":"2275_CR19","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jtho.2018.10.001","volume":"14","author":"AS Mansfield","year":"2019","unstructured":"Mansfield AS, Peikert T, Smadbeck JB, et al. Neoantigenic potential of complex chromosomal rearrangements in mesothelioma. J Thorac Oncol. 2019;14:276\u201387.","journal-title":"J Thorac Oncol"},{"key":"2275_CR20","doi-asserted-by":"publisher","first-page":"15180","DOI":"10.1038\/ncomms15180","volume":"8","author":"I Cortes-Ciriano","year":"2017","unstructured":"Cortes-Ciriano I, Lee S, Park WY, Kim TM, Park P. A molecular portrait of microsatellite instability across multiple cancers. Nature communications. 2017;8:15180. https:\/\/doi.org\/10.1038\/ncomms15180.","journal-title":"Nature communications"},{"key":"2275_CR21","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrm1907","volume":"7","author":"J Jiricny","year":"2006","unstructured":"Jiricny J. The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol. 2006;7:335\u201346.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2275_CR22","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1136\/gut.47.1.37","volume":"47","author":"H Iino","year":"2000","unstructured":"Iino H, Simms L, Young J, Arnold J, Winship IM, Webb SI, Furlong KL, Leggett B, Jass JR. DNA microsatellite instability and mismatch repair protein loss in adenomas presenting in hereditary nonpolyposis colorectal cancer. Gut. 2000;47:37\u201342.","journal-title":"Gut"},{"key":"2275_CR23","doi-asserted-by":"crossref","first-page":"7810","DOI":"10.1158\/0008-5472.CAN-06-1114","volume":"66","author":"H Hampel","year":"2006","unstructured":"Hampel H, Frankel W, Panescu J, Lockman J, Sotamaa K, Fix D, Comeras I, La Jeunesse J, Nakagawa H, Westman JA, Prior TW, Clendenning M, Penzone P, Lombardi J, Dunn P, Cohn DE, Copeland L, Eaton L, Fowler J, Lewandowski G, Vaccarello L, Bell J, Reid G, de la Chapelle A. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res. 2006;66:7810\u20137.","journal-title":"Cancer Res"},{"key":"2275_CR24","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3892\/mco.2015.506","volume":"3","author":"L Zhu","year":"2015","unstructured":"Zhu L, Wang Y, Zhang C, Liu Y, Qu X. microsatellite instability and survival in gastric cancer: a systematic review and meta-analysis. Mol Clin Oncol. 2015;3:699\u2013705.","journal-title":"Mol Clin Oncol"},{"key":"2275_CR25","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jmoldx.2010.12.004","volume":"13","author":"MS Cicek","year":"2011","unstructured":"Cicek MS, Lindor NM, Gallinger S, Bapat B, Hopper JL, Jenkins MA, Young J, Buchanan D, Walsh MD, Le Marchand L, et al. Quality assessment and correlation of microsatellite instability and immunohistochemical markers among population- and clinic-based colorectal tumors results from the Colon Cancer Family Registry. J Mol Diagn. 2011;13:271\u201381.","journal-title":"J Mol Diagn"},{"key":"2275_CR26","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1373\/clinchem.2014.223677","volume":"60","author":"SJ Salipante","year":"2014","unstructured":"Salipante SJ, Scroggins SM, Hampel HL, et al. Microsatellite instability detection by next generation sequencing. Clin Chem. 2014;60:1192\u20139.","journal-title":"Clin Chem"},{"key":"2275_CR27","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1093\/bioinformatics\/btt755","volume":"30","author":"B Niu","year":"2013","unstructured":"Niu B, Ye K, Zhang Q, et al. MSIsensor: microsatellite instability detection using paired tumor-normal sequence data. Bioinformatics. 2013;30:1015\u20136.","journal-title":"Bioinformatics"},{"key":"2275_CR28","doi-asserted-by":"crossref","first-page":"7452","DOI":"10.18632\/oncotarget.13918","volume":"8","author":"EA Kautto","year":"2016","unstructured":"Kautto EA, Bonneville R, Miya J, et al. Performance evaluation for rapid detection of pan-cancer microsatellite instability with MANTIS. Oncotarget. 2016;8:7452\u201363.","journal-title":"Oncotarget"},{"key":"2275_CR29","doi-asserted-by":"publisher","DOI":"10.1200\/PO17.00073","author":"R Bonneville","year":"2017","unstructured":"Bonneville R, Krook M, Kautto E, Miya J, Wing M, et al. Landscape of microsatellite instability across 39 cancer types. JCO Precis Oncol. 2017. https:\/\/doi.org\/10.1200\/PO17.00073.","journal-title":"JCO Precis Oncol"},{"key":"2275_CR30","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"D Le","year":"2015","unstructured":"Le D, Uram J, Wang H, Barlett B, Kemberling H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509\u201320.","journal-title":"N Engl J Med"},{"issue":"10","key":"2275_CR31","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/j.jtho.2018.07.015","volume":"13","author":"S Arulananda","year":"2018","unstructured":"Arulananda S, Thapa B, Walkiewicz M, et al. Mismatch repair protein defects and microsatellite instability in malignant pleural mesothelioma. J Thorac Oncol. 2018;13(10):1588\u201394.","journal-title":"J Thorac Oncol"},{"key":"2275_CR32","unstructured":"Rami-Porta R. Staging manual in thoracic oncology from inetrnational association for the study of lung cancer. ISBN:978\u20130\u20139832958\u20134\u20136"},{"key":"2275_CR33","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/annonc\/mdz116","volume":"30","author":"C Luchini","year":"2019","unstructured":"Luchini C, Bibeau F, Ligtenberg J, Singh N, Nottegar A, et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1\/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann Oncol. 2019;30:1232\u201343.","journal-title":"Ann Oncol"},{"issue":"4","key":"2275_CR34","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","volume":"17","author":"M Schemper","year":"1996","unstructured":"Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Controll Clin Trials. 1996;17(4):343\u20136.","journal-title":"Controll Clin Trials"},{"issue":"3","key":"2275_CR35","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1056\/NEJMoa022289","volume":"349","author":"CM Ribic","year":"2003","unstructured":"Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, Hamilton SR, Laurent-Puig P, Gryfe R, Shepherd LE, Tu D, Redston M, Gallinger S. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349(3):247\u201357.","journal-title":"N Engl J Med"},{"issue":"7","key":"2275_CR36","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1200\/JCO.2006.05.8172","volume":"25","author":"GP Kim","year":"2007","unstructured":"Kim GP, Colangelo LH, Wieand HS, Paik S, Kirsch IR, Wolmark N, Allegra CJ. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol. 2007;25(7):767\u201372.","journal-title":"J Clin Oncol"},{"key":"2275_CR37","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/bjc.2016.161","volume":"115","author":"C Kim","year":"2016","unstructured":"Kim C, Ahn J, Jung M, Beom S, Kim C, Kim J, et al. effects of microsatellite instability on recurrence patterns and outcomes in colorectal cancers. Br J Cancer. 2016;115:25\u201333.","journal-title":"Br J Cancer"},{"key":"2275_CR38","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","volume":"18","author":"M Overman","year":"2017","unstructured":"Overman M, McDermott R, Lleach J, Lonardi S, Lenz H, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18:1182\u201391.","journal-title":"Lancet Oncol"},{"key":"2275_CR39","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5858\/arpa.2017-0040-RA","volume":"142","author":"E Marginean","year":"2018","unstructured":"Marginean E, Melosky B. Is there a role for programmed death ligand-1 testing and immunotherapy in colorectal cancer with microsatellite instability? Arch Pathol Lab Med. 2018;142:17\u201325.","journal-title":"Arch Pathol Lab Med"},{"key":"2275_CR40","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2353\/jmoldx.2008.080031","volume":"10","author":"J Shia","year":"2008","unstructured":"Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal Cancer patients at risk for hereditary nonpolyposis colorectal Cancer syndrome. J Mol Diagn. 2008;10:293\u2013300.","journal-title":"J Mol Diagn"},{"key":"2275_CR41","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1097\/01.pas.0000213428.61374.06","volume":"31","author":"I Modica","year":"2007","unstructured":"Modica I, Soslow RA, Black D, Tornos C, Kauff N, Shia J. Utility of immunohistochemistry in predicting microsatellite instability in endometrial carcinoma. Am J Surg Pathol. 2007;31:744\u201351.","journal-title":"Am J Surg Pathol"},{"key":"2275_CR42","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/jmedgenet-2014-102284","volume":"51","author":"K Wimmer","year":"2014","unstructured":"Wimmer K, Krtaz C, Vasen H, Caron O, Colas C, et al. Diagnostic criterai for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium \u201cCare for CMMRD\u201d (C4CMMRD). J Med Genetic. 2014;51:355\u201365.","journal-title":"J Med Genetic"},{"key":"2275_CR43","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1053\/j.gastro.2015.06.013","volume":"149","author":"S Bodo","year":"2015","unstructured":"Bodo S, Colas C, Buhard O, Collura A, Tinat J, et al. Diagnosis of constitutional mismatch repair-deficiency syndrome based on microsatellite instability and lymphocyte tolerance to methylating agents. Gastroenterology. 2015;149:1017\u201329.","journal-title":"Gastroenterology"},{"key":"2275_CR44","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.celrep.2016.03.075","volume":"15","author":"M Giannakis","year":"2016","unstructured":"Giannakis M, Mu X, Shukla S, et al. Genomic correlates of immune-cell infiltrates in colorectal carcinoma. Cell Rep. 2016;15:857\u201365.","journal-title":"Cell Rep"},{"key":"2275_CR45","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348:124\u20138.","journal-title":"Science"},{"key":"2275_CR46","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","volume":"371","author":"A Snyder","year":"2014","unstructured":"Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371:2189\u201399.","journal-title":"N Engl J Med"},{"key":"2275_CR47","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636\u201344.","journal-title":"J Clin Oncol"},{"key":"2275_CR48","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","volume":"387","author":"G Zalcman","year":"2016","unstructured":"Zalcman G, Mazieres J, Margery J, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387:1405\u201314.","journal-title":"Lancet"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-019-02275-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12094-019-02275-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-019-02275-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T07:51:15Z","timestamp":1665388275000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12094-019-02275-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,8]]},"references-count":48,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["2275"],"URL":"https:\/\/doi.org\/10.1007\/s12094-019-02275-9","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,8]]},"assertion":[{"value":"16 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Approval for the use of the tissue in research was obtained from the ethical local committee from both hospitals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients gave written inform consent before enrollment.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}